Triple

T22717590
Position Surface form Disambiguated ID Type / Status
Subject Genzyme E561775 entity
Predicate hasProduct P3585 FINISHED
Object Fabrazyme
Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
 E1551498 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Fabrazyme | Statement: [Genzyme, hasProduct, Fabrazyme]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Fabrazyme
Context triple: [Genzyme, hasProduct, Fabrazyme]
  • A. Cerezyme
    Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
  • B. Genzyme
    Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
  • C. Lumizyme
    Lumizyme is an enzyme replacement therapy used to treat patients with Pompe disease by supplementing deficient acid alpha-glucosidase.
  • D. Hemlibra
    Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
  • E. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Fabrazyme
Triple: [Genzyme, hasProduct, Fabrazyme]
Generated description
Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Fabrazyme
Target entity description: Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
  • A. Cerezyme
    Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
  • B. Genzyme
    Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
  • C. Lumizyme
    Lumizyme is an enzyme replacement therapy used to treat patients with Pompe disease by supplementing deficient acid alpha-glucosidase.
  • D. Hemlibra
    Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
  • E. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454fc984819088213b58ee87a002 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1790ecbc48190926d16b20b674dbd completed April 29, 2026, 3:20 a.m.
NED1 Entity disambiguation (via context triple) batch_6a0b8fbe82fc8190a783458a6aba1f6b completed May 18, 2026, 10:16 p.m.
NEDg Description generation batch_6a0b90eb442481909bac0fc11e3a50be completed May 18, 2026, 10:21 p.m.
NED2 Entity disambiguation (via description) batch_6a0b9153b6f88190982da7a3ed3774ff completed May 18, 2026, 10:23 p.m.
Created at: April 17, 2026, 3:19 p.m.